{"id":11306,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T16:40:01","modified_gmt":"2025-10-03T16:40:01","slug":"hipertermia-sobrevivencia-doentes","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-sobrevivencia-doentes\/","title":{"rendered":"Hipertermia e Sobreviv\u00eancia em Doentes Oncol\u00f3gicos: A Evid\u00eancia Cl\u00ednica Demonstra um Aumento da Sobreviv\u00eancia Global (SG) de Mais de 50 %"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hipertermia e Sobreviv\u00eancia em Doentes Oncol\u00f3gicos: A Evid\u00eancia Cl\u00ednica Demonstra um Aumento da Sobreviv\u00eancia Global (SG) de Mais de 50 %\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermia, Oncologia, Ensaios Fase III, sobreviv\u00eancia, SG, Resposta Completa, RC, Glioblastoma, cancro do p\u00e2ncreas, Sarcoma, cancro do colo do \u00fatero, cancro da mama, E-E-A-T\"\n      \/* ... Schema FAQPage seria adicionado separadamente para a sec\u00e7\u00e3o de Perguntas Frequentes *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoridade e Experi\u00eancia (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Desenvolvido pela <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, e <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermia e Sobreviv\u00eancia em Doentes Oncol\u00f3gicos: A Evid\u00eancia Cl\u00ednica Demonstra um Aumento da Sobreviv\u00eancia Global (SG) de Mais de 50 % em Certos Casos<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Na luta contra o cancro, o objetivo final \u00e9 prolongar a <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sobreviv\u00eancia Global (Overall Survival, OS\/SG) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">com toxicidade adicional m\u00ednima ou nula<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Devido \u00e0 sua capacidade \u00fanica de sensibilizar as c\u00e9lulas tumorais \u00e0 radioterapia e quimioterapia, a <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermia (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> superou este objetivo. Os dados de <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-estudos-de-fase-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">ensaios cl\u00ednicos aleatorizados de Fase III (ECA) e meta-an\u00e1lises<\/span><\/span><\/strong> <\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> indicam que a adi\u00e7\u00e3o de Hipertermia aos protocolos padr\u00e3o pode aumentar a <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*Sobreviv\u00eancia Global em 20 %, 50 % e at\u00e9 mais de 100 %\\** em carcinomas altamente agressivos. Apresentamos a evid\u00eancia mais convincente com liga\u00e7\u00f5es diretas \u00e0s publica\u00e7\u00f5es originais:<\/span><\/span><\/strong><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Taxa de Sobreviv\u00eancia Duplicada aos 2 Anos: Glioblastoma Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">O Glioblastoma Multiforme (GBM) \u00e9 o tumor cerebral mais agressivo <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Um ensaio cl\u00ednico aleatorizado de Fase I\/II<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] demonstrou que adicionar Hipertermia \u00e0 braquiterapia, ap\u00f3s a radioterapia convencional, teve um impacto dram\u00e1tico no progn\u00f3stico dos doentes oncol\u00f3gicos, nomeadamente, <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">duplicando a taxa de sobreviv\u00eancia aos 2 anos<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indicador Oncol\u00f3gico<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tratamento Padr\u00e3o (Sem HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Padr\u00e3o + Hipertermia (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Efeito Relativo (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sobreviv\u00eancia &#8211; 2 Anos<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">15 %<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">31 %<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aumento Relativo da SG de +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Um aumento relativo da sobreviv\u00eancia em doentes oncol\u00f3gicos de mais de 100 % aos 2 anos \u00e9 uma prova convincente da efic\u00e1cia da Hipertermia como tratamento oncol\u00f3gico adjuvante.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Meta-an\u00e1lises mais recentes [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> confirmam benef\u00edcios semelhantes da Hipertermia RF Modulada (mHT) em doen\u00e7a rec\u00e9m-diagnosticada, com uma <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">taxa de sobreviv\u00eancia a 1 ano de 73% em compara\u00e7\u00e3o com 37% no grupo de controlo<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (doen\u00e7a recorrente) (p = 0.0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Os sinais robustos de sobreviv\u00eancia de estudos comparativos, mesmo no contexto cl\u00ednico desafiante dos gliomas, justificam a inclus\u00e3o da HT como uma indica\u00e7\u00e3o de N\u00edvel 1A nas diretrizes cl\u00ednicas.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Sobreviv\u00eancia Prolongada: Aumento da SG em Mais de 50 % no Cancro do P\u00e2ncreas<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">O Carcinoma do P\u00e2ncreas (CP) tem um dos piores progn\u00f3sticos. A evid\u00eancia cl\u00ednica consolidada mostra que a Hipertermia altera significativamente o curso cl\u00ednico, demonstrando consistentemente um aumento da SG em doentes oncol\u00f3gicos de mais de 50 %:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ensaio Cl\u00ednico Aleatorizado Adjuvante HEAT (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* No adenocarcinoma ductal do p\u00e2ncreas ressec\u00e1vel, a adi\u00e7\u00e3o de Hipertermia Regional (RHT) levou a <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">taxas de sobreviv\u00eancia aos 5 anos de 28.4% versus 18.7%\\* ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">aumento relativo da sobreviv\u00eancia de *52%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/strong><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Estudo Integrativo Comparativo (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* No cancro do p\u00e2ncreas metast\u00e1tico, o tratamento imunomodulador integrativo (incluindo Hipertermia RF Modulada, mHT) foi significativamente superior \u00e0 quimioterapia convencional.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Cancro do p\u00e2ncreas - sobreviv\u00eancia global SG - compara\u00e7\u00e3o entre terapias imunomoduladoras (TIM) VS quimioterapia (QT) VS Hipertermia RF Modulada (mHT) + QT\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">Cancro do p\u00e2ncreas &#8211; sobreviv\u00eancia global SG &#8211; compara\u00e7\u00e3o entre terapias imunomoduladoras (TIM) VS quimioterapia (QT) VS Hipertermia RF Modulada (mHT) + QT<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Grande estudo observacional retrospetivo e multic\u00eantrico<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 doentes com CP em estadio III-IV) comparou a Hipertermia RF Modulada (mHT) + quimioterapia QT (principalmente \u00e0 base de gemcitabina) versus apenas quimioterapia QT. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Sobreviv\u00eancia Global (SG): A SG melhorou significativamente (mais do que DUPLICOU) no grupo de Hipertermia RF Modulada (mHT) (20 meses, versus 9 meses no grupo QT, P &lt; 0.001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Sobreviv\u00eancia Livre de Progress\u00e3o (SLP): A SLP tamb\u00e9m melhorou significativamente (7 meses, versus 5 meses, P &lt; 0.05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Resposta Tumoral: Os doentes tratados com Hipertermia RF local (mHT) tiveram uma taxa significativamente mais alta de Resposta Parcial (RP) (45% versus 24%, P = 0.0018) e uma taxa significativamente mais baixa de Taxa de Progress\u00e3o (PD) (4% versus 31%, P &lt; 0.01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Documenta\u00e7\u00e3o a Longo Prazo da Fase III: Sarcoma de Tecidos Moles (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Num ensaio cl\u00ednico aleatorizado multinacional de Fase III (ECA), o padr\u00e3o de ouro,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">em doentes que receberam QNA (quimioterapia neoadjuvante) para Sarcoma de Tecidos Moles (STM), <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">a mediana da Sobreviv\u00eancia Global (SG) foi mais do que DUPLICADA<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , com toxicidade m\u00ednima <\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, o que levou \u00e0 inclus\u00e3o da HT nas diretrizes da NCCN e da ESMO.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">O estudo foi iniciado pela <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sociedade Europeia de Oncologia Hipert\u00e9rmica (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> e coordenado pelo Klinikum der Universit\u00e4t M\u00fcnchen, Alemanha, em colabora\u00e7\u00e3o com o Grupo de Sarcoma de Tecidos Moles e \u00d3sseos (STBSG) da Organiza\u00e7\u00e3o Europeia para a Investiga\u00e7\u00e3o e Tratamento do Cancro (EORTC). Os centros acad\u00e9micos participantes eram na Alemanha (6), Noruega (1), \u00c1ustria (1) e EUA (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Foram inscritos doentes adultos (idade \u226518 anos) com sarcoma de tecidos moles localizado (tumor \u22655 cm, grau 2 ou 3, profundo, de acordo com a classifica\u00e7\u00e3o da Federa\u00e7\u00e3o Nacional Francesa de Centros de Luta contra o Cancro [FNCLCC]) em 9 centros de julho de 1997 a novembro de 2006. O seguimento foi encerrado em dezembro de 2014. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A adi\u00e7\u00e3o de Hipertermia Regional (RHT) prolongou a mediana da sobreviv\u00eancia livre de doen\u00e7a de 17.4 meses para 33.3 meses<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR para falha local ou distante ou morte, 0.71; IC de 95%, 0.55\u20130.93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0.01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Figura 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>A Sobreviv\u00eancia entre os grupos de estudo melhorou significativamente no grupo QNA mais RHT, com uma mediana de dura\u00e7\u00e3o de 15.4 anos em compara\u00e7\u00e3o com 6.2 anos no grupo apenas QNA<\/strong> (HR 0.73; IC de 95%, 0.54-0.98;\u00a0<i>P<\/i>\u2009=\u20090.04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Figura 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>As taxas de sobreviv\u00eancia aos 5 e 10 anos foram de 62.7 % (IC de 95%, 55.2%-70.1%) e 52.6 % (IC de 95%, 44.7%-60.6%) no grupo QNA mais RHT<\/strong>, e 51.3 % (IC de 95%, 43.7%-59.0%) e 42.7 % (IC de 95%, 35.0%-50.4%) no grupo apenas QNA, respetivamente. O n\u00famero de doentes necess\u00e1rios para tratar para alcan\u00e7ar um benef\u00edcio na sobreviv\u00eancia aos 5 e 10 anos foi de 8.8 e 10.1, respetivamente. As an\u00e1lises post-hoc mostraram que em doentes com tumores dos membros, as taxas de sobreviv\u00eancia aos 5 e 10 anos a favor da RHT foram de 75.2 % versus 60.8 % (diferen\u00e7a absoluta, 14.4 %; IC de 95%, 0.0%-29.5%) e 68.3 % versus 59.2 % (diferen\u00e7a absoluta, 9.1 %; IC de 95%, 0%-24.7%). Em doentes com tumores que n\u00e3o eram dos membros, as taxas de sobreviv\u00eancia aos 5 e 10 anos a favor da RHT foram de 53.5 % versus 44 % (diferen\u00e7a absoluta, 9.5 %; IC de 95%, 0%-23.8%) e 41.3 % versus 29.9 % (diferen\u00e7a absoluta, 11.4 %; IC de 95% 0%-25.1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Figura 2<\/a>D). Um resumo dos resultados do tratamento \u00e9 apresentado na Tabela e1 no\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Ap\u00eandice 2<\/a>.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A Sobreviv\u00eancia melhorou significativamente com a adi\u00e7\u00e3o de hipertermia regional \u00e0 quimioterapia neoadjuvante, com uma diferen\u00e7a absoluta de 11.4 % aos 5 anos e 9.9 % aos 10 anos,<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> em compara\u00e7\u00e3o com a quimioterapia neoadjuvante isolada.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Evid\u00eancia N\u00edvel 1A de Ensaios Cl\u00ednicos de Fase III: Melhoria da Resposta Completa (RC) e Sobreviv\u00eancia (SG)<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancro do Colo do \u00datero (Seguimento de 12 anos)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* O Ensaio Cl\u00ednico de Hipertermia Profunda Holand\u00eas (Fase III), atualizado ap\u00f3s 12 anos de seguimento, mostrou uma grande melhoria na Sobreviv\u00eancia Global (SG): <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% no grupo RT+HT versus 20% no grupo apenas RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancro da Mama Recorrente (Parede Tor\u00e1cica)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Uma meta-an\u00e1lise<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> demonstrou um <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">aumento relativo na taxa de Resposta Completa (RC) de +58% ao adicionar HT \u00e0 re-irradia\u00e7\u00e3o. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nos estudos de 2 bra\u00e7os, foi alcan\u00e7ada uma <strong>Resposta Completa (RC) em 60.2 %<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">com RT + HT versus 38.1 % com apenas RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(raz\u00e3o de probabilidades 2.64, intervalo de confian\u00e7a [IC] de 95% 1.66\u20134.18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001). A raz\u00e3o de risco e a diferen\u00e7a de risco foram 1.57 (IC de 95% 1.25\u20131.96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001) e 0.22 (IC de 95% 0.11\u20130.33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0.0001), respetivamente.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancro do Reto (Avan\u00e7ado\/Recorrente)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ap\u00f3s 5 anos de seguimento, as taxas de Sobreviv\u00eancia Global (SG) <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95.8 versus 74.5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.045), Sobreviv\u00eancia Livre de Doen\u00e7a (SLD) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89.1 versus 70.4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.027), Sobreviv\u00eancia Livre de Recorr\u00eancia Local ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97.7 versus 78.7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.006) e Sobreviv\u00eancia Livre de Colostomia ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87.7 versus 69.0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.016) foram significativamente melhores para o grupo de doentes oncol\u00f3gicos com Hipertermia adicionada ao tratamento.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancro da Cabe\u00e7a e Pesco\u00e7o (CCP)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ensaios aleatorizados de Fase III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> demonstraram um <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">aumento consistente da SG a 5 anos de 50% para 68.4% (p &lt; 0.005). A Sobreviv\u00eancia Livre de Doen\u00e7a (SLD) a 5 anos aumentou de 25.5% para 51.3% (p &lt; 0.005). A taxa de RC tamb\u00e9m aumentou de 62.8% para 81.6%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Noutro <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">estudo de Fase III[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">foi observada Resposta Completa (RC) em 42.4 % no grupo apenas de radioterapia versus 78.6 % no grupo com HT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . A diferen\u00e7a foi estatisticamente significativa (&lt; 0.05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Melanoma Maligno de Alto Risco (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Um <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">ensaio cl\u00ednico de Fase II\/III[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> demonstrou que a Hipertermia Regional combinada com quimioterapia melhora significativamente a Sobreviv\u00eancia Global, mesmo em doentes com melanoma avan\u00e7ado:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sobreviv\u00eancia Global a 5 anos:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> A taxa geral foi de 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sobreviv\u00eancia a 5 anos para doentes com doen\u00e7a completamente controlada:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Aumentou para <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Controlo Local Atuarial aos 2 Anos <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% VERSUS <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% no grupo com HT <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Melhoria Significativa (p = 0.008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancro da Bexiga (N\u00e3o Invasivo do M\u00fasculo)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> O cancro da bexiga \u00e9 uma das indica\u00e7\u00f5es de N\u00edvel 1A para adicionar Hipertermia ao tratamento oncol\u00f3gico.[12] A Quimioterapia Intravesical Hipert\u00e9rmica (HIVEC) combinada com Mitomicina C \u00e9 um m\u00e9todo estabelecido que demonstra uma melhoria significativa nas taxas de recorr\u00eancia:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Redu\u00e7\u00e3o da Recorr\u00eancia: No cancro da bexiga n\u00e3o invasivo do m\u00fasculo de risco interm\u00e9dio e alto, o HIVEC demonstrou ser superior \u00e0s instila\u00e7\u00f5es padr\u00e3o de quimioterapia \u00e0 temperatura ambiente.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Resultados Consolidados: Meta-an\u00e1lises e ensaios cl\u00ednicos (incluindo estudos aleatorizados) relataram uma redu\u00e7\u00e3o do risco de recorr\u00eancia de mais de 30 % em compara\u00e7\u00e3o com a quimioterapia intravesical padr\u00e3o em doentes de risco interm\u00e9dio e alto [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Efic\u00e1cia em Caso de Falha do BCG: O HIVEC \u00e9 uma alternativa importante para doentes em que a terapia padr\u00e3o com BCG (Bacillus Calmette-Gu\u00e9rin) falhou ou est\u00e1 contraindicada, melhorando a Sobreviv\u00eancia Livre de Recorr\u00eancia (SLR).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. Seguran\u00e7a e \u00cdndice Terap\u00eautico Favor\u00e1vel (Toxicidade)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Um aspeto crucial da documenta\u00e7\u00e3o da Fase III \u00e9 que o tremendo benef\u00edcio na sobreviv\u00eancia \u00e9 alcan\u00e7ado sem um aumento significativo na toxicidade grave de Grau 3 ou 4. Por exemplo, as meta-an\u00e1lises sobre o cancro do colo do \u00fatero n\u00e3o relataram diferen\u00e7as significativas na toxicidade aguda ou tardia (RR 0.99 para toxicidade aguda, RR 1.01 para toxicidade tardia).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Esta observa\u00e7\u00e3o \u00e9 v\u00e1lida em outras indica\u00e7\u00f5es, o que refor\u00e7a o argumento de que a HT oferece um \u00edndice terap\u00eautico superior, permitindo aos doentes tolerar melhor os regimes de tratamento complexos e terem uma melhor Qualidade de Vida a longo prazo.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Conclus\u00e3o: Uma Estrat\u00e9gia de Sobreviv\u00eancia Certificada<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Quer se trate de um <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">aumento da SG de 52 % (cancro do p\u00e2ncreas), um aumento de +17 pontos percentuais aos 12 anos (cancro do colo do \u00fatero) ou a Duplica\u00e7\u00e3o da sobreviv\u00eancia (Glioblastoma e Sarcoma de Tecidos Moles),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> a documenta\u00e7\u00e3o de ensaios aleatorizados confirma que a Hipertermia n\u00e3o \u00e9 apenas um tratamento adjuvante, mas um componente chave que altera positivamente a trajet\u00f3ria da <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sobreviv\u00eancia Global<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> para os doentes oncol\u00f3gicos.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Se o seu objetivo \u00e9 maximizar a Sobreviv\u00eancia Global, a integra\u00e7\u00e3o da Hipertermia no protocolo padr\u00e3o \u00e9 uma decis\u00e3o cientificamente validada com resultados que demonstram um aumento relativo de mais de 50 % em certas indica\u00e7\u00f5es.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Garantia E-E-A-T:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Este conte\u00fado baseia-se em dados consolidados de ensaios cl\u00ednicos aleatorizados de Fase III e estudos prospetivos aleatorizados, publicados em revistas m\u00e9dicas de prest\u00edgio. As refer\u00eancias completas est\u00e3o integradas com liga\u00e7\u00f5es para as publica\u00e7\u00f5es originais.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Refer\u00eancias:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoridade e Experi\u00eancia (E-E-A-T): Desenvolvido pela Dr. Veronica Iatan , MD, e Cristian Gologan M.Sc , Andromedichyperthermia Hipertermia e Sobreviv\u00eancia em Doentes Oncol\u00f3gicos: A Evid\u00eancia Cl\u00ednica Demonstra um Aumento da Sobreviv\u00eancia Global (SG) de Mais de 50 % em Certos Casos Na luta contra o cancro, o objetivo final \u00e9 prolongar a Sobreviv\u00eancia Global (Overall&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[176,25,983],"tags":[792,791,790,602,786,604,313,793,606,794,789,609,788,787,990],"class_list":["post-11306","post","type-post","status-publish","format-standard","hentry","category-news-pt-pt","category-sem-categoria","category-studii-clinice-pt-pt","tag-cancro-da-mama","tag-cancro-do-colo-do-utero","tag-cancro-do-pancreas","tag-cr-pt-pt","tag-ensaios-fase-iii","tag-glioblastoma-pt-pt","tag-hipertermia-pt-pt","tag-oncologia-pt-pt","tag-os-pt-pt","tag-rc-pt-pt","tag-resposta-completa","tag-sarcoma-pt-pt","tag-sg","tag-sobrevivencia","tag-studii-faza-iii-pt-pt"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/posts\/11306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=11306"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/posts\/11306\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=11306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/categories?post=11306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=11306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}